Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	2.96B
Revenue (ttm)	878.05M
Net Income (ttm)	97.02M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	30.51
Forward PE	20.73
Dividend	0.02 (1.73%)
Ex-Dividend Date	Jun 18, 2025

Volume	111
Average Volume	72
Open	1.120
Previous Close	1.080
Day's Range	1.120 - 1.120
52-Week Range	0.585 - 1.420
Beta	n/a
RSI	45.57
Earnings Date	Aug 21, 2025

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY